Edding Genor Group Holdings Limited (HKG:6998)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
1.930
-0.070 (-3.50%)
Jun 1, 2026, 4:08 PM HKT
Market Cap3.98B
Revenue (ttm)2.77B -2.3%
Net Income444.30M +2.9%
EPS0.26 +1.0%
Shares Out 1.99B
PE Ratio7.65
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,383,000
Open2.000
Previous Close2.000
Day's Range1.890 - 2.050
52-Week Range1.880 - 5.600
Beta0.85
Analystsn/a
Price Targetn/a
Earnings DateMar 27, 2026

About HKG:6998

Edding Genor Group Holdings Limited, together with its subsidiaries, engages in the research, development, manufacturing, and distribution of biopharmaceutical products in China, the United States, and internationally. The company offers GB491, a differentiated CDK4/6 inhibitor for advanced or metastatic breast cancer; GB261, a novel CD3/CD20 bispecific antibody which is in Phase III clinical trial for autoimmune diseases; and GB263T and GB268, tri-specific antibody candidates which are Phase I clinical trial. It also provides Vancocin for mult... [Read more]

Sector Healthcare
Founded 2001
Employees 1,545
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 6998
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements